Transcriptomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented by Component (Instruments, Consumables, Software & Services), By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Microarray, In-Situ Hybridization, Others), By Application (Drug Discovery & Development, Cell Biology, Single Cell Analysis, Gene Expression, Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Region and Competition

The global transcriptomics market is anticipated to witness an impressive growth during the forecast period. This can be ascribed to the growing application of RNA sequencing and NGS for the diagnosis of genetic illness in the developing countries. Additionally, growing initiative and investments by government organizations for developing new technology, with the introduction of new microarray technology have significantly increased the demand for transcriptomics across different parts of the globe. Additionally, rising adoption of new technology and growing demand for personalized medicine for treatments are further expected to increase the demand for transcriptomics, thereby fuelling the market growth through 2028. Furthermore, increasing number of biopharmaceutical companies and growing expenditure on research and development are further expected to increase the demand for transcriptomics, thereby supporting the market growth. Every 4 1/2 minutes, a baby is born with a birth defect in United States every year and affects 1 in every 33 babies born in the United States each year. That translates into about 120,000 babies. Transcriptomics is the study of the transcriptome, which is the complete set of RNA transcripts that are produced by the genome. Transcriptomics allows researchers to investigate gene expression patterns, identify disease-associated biomarkers, and develop personalized treatment strategies. The global transcriptomics market includes products and services that are used in transcriptomics research, such as microarrays, next-generation sequencing (NGS) technologies, and bioinformatics tools. NGS technologies, such as RNA sequencing (RNA-seq), have become increasingly popular in transcriptomics research due to their ability to provide high-throughput, accurate, and quantitative measurements of gene expression. The market for NGS technologies is expected to dominate the global transcriptomics market during the forecast period. In personalized medicine, transcriptomics is used to develop targeted therapies that are tailored to the individual patient's genetic profile. Transcriptomics can also be used to identify patients who are at risk of developing certain diseases and to develop strategies for disease prevention and early detection. In clinical diagnostics, transcriptomics can be used to identify disease-associated biomarkers and to develop new diagnostic tests. Transcriptomics can also be used to monitor the response to treatment and to identify potential drug interactions. Transcriptomics research requires a significant investment in equipment, reagents, and bioinformatics tools, which can be prohibitively expensive for some researchers and institutions. This could limit the adoption of transcriptomics technologies, particularly in emerging markets. Transcriptomics research requires specialized expertise in molecular biology, genomics, and bioinformatics. The shortage of skilled professionals in these areas could limit the growth of the market and lead to a lack of innovation. Transcriptomics data is complex and requires sophisticated bioinformatics tools for analysis. Many researchers may lack the expertise or resources to analyze this data effectively, which could limit the utility of transcriptomics technologies. The lack of standardization in transcriptomics research can make it difficult to compare results across different studies and platforms. This could limit the reproducibility and reliability of transcriptomics data, which could impact its utility in drug discovery and clinical diagnostics. Transcriptomics research raises ethical and legal concerns related to privacy, confidentiality, and informed consent. Addressing these concerns is critical to ensuring that transcriptomics research is conducted ethically and responsibly.

Increasing Demand for Personalized Medicine

Increasing demand for precision medicine & genetic testing, and increasing prevalence of conditions such as obesity, hepatitis B, and cancer are expected to boost the market for transcriptomics technology. Additionally, increasing the incidence of genetic mutations related diseases such as down syndrome due to arising in carcinogens and genetic variants among the population is expected to propel the market growth during the forecast period. The increasing prevalence of cancer is expected to offer lucrative growth opportunities for players in the global transcriptomics technologies market. For instance, according to the American Cancer Society, in 2019, total estimated 1,762,450 new cancer cases were diagnosed and 606,880 cancer deaths in the U.S. Particularly next-generation sequencing (NGS) has transformed the diagnosis of genetic illnesses and allowed medical professionals to offer even more thorough clinical insights. For instance, in April 2020, Indivumed GmbH, an oncology company, launched the Oncology Alliance for Individualized Medicine, an international collaborative alliance to advance personalized medicine in cancer through IndivuType, the company’s multi-omics database. With the rising prevalence of chronic diseases and the need for more effective treatment options, personalized medicine has become a key focus of the healthcare industry. Transcriptomics plays a critical role in personalized medicine by enabling researchers to identify disease-associated biomarkers and develop targeted therapies. Transcriptomics has emerged as a key technology in the field of precision medicine, as researchers seek to develop personalized treatments that are tailored to the individual patient's genetic profile. Transcriptomics can be used to identify biomarkers that are associated with disease, which can be used to develop targeted therapies.

Growing Development of the Healthcare Industry

Due to the increasing technical developments in research and development sector and the use of RNA sequencing technology in analytical science, the demand for transcriptomics technology is expected to create a lucrative growth in the forecast period. Private and government organizations are supporting the research and development sector by the help of pharmaceutical and biotechnology firms which will further boost the market growth in the forecast period. The funding for cancer research has rapidly increased and most of the government funding centers breast cancer and childhood cancer. In 2019, the NIH of the US government invested USD460 million in breast cancer which has increased to USD3.5 billion in the year of 2022. Governments around the world are increasingly investing in genomics research, including transcriptomics, to advance scientific understanding and develop new treatments for diseases. This funding has led to the establishment of research centers and collaborations between academic and industry players, driving the growth of the transcriptomics market. NGS technologies, such as RNA sequencing (RNA-seq), have revolutionized the field of transcriptomics by providing high-throughput, accurate, and quantitative measurements of gene expression. Advancements in NGS technologies, such as the development of single-cell sequencing technologies, have further fueled the growth of the transcriptomics market. Transcriptomics is increasingly being used in drug discovery and development to identify new drug targets, understand drug mechanisms of action, and develop more effective treatments. As a result, the demand for transcriptomics products and services has increased in the biotech and pharmaceutical industries. Biomarkers are critical for the early detection, diagnosis, and treatment of diseases. Transcriptomics enables researchers to identify biomarkers associated with various diseases, leading to the development of new diagnostic and therapeutic tools. This has driven the demand for transcriptomics products and services in clinical diagnostics and biomarker discovery.

Recent Development

• In May 2022, BioSkryb Genomics first announced the Early Access Program (EAP) for ResolveOME. With this one-cell process, the whole genome and full-length mRNA transcripts of the whole transcriptome can be amplified from a single cell.
• In January 2022, Parse Biosciences, a company that helps researchers with single-cell sequencing, made a deal with Research Instruments Ptv Ltd to sell Parse's Evercore Whole Transcriptome Kits (WTKs), Cell Fixation Kits, and Nuclei Fixation Kits in Singapore and the rest of Southeast Asia.
• 10x Genomics Chromium Single Cell Gene Expression Solution: This platform was launched in 2018 and enables the high-throughput analysis of gene expression in individual cells. The platform is widely used in research and drug discovery applications.
• Illumina NovaSeq 6000 System: This system was launched in 2017 and is a high-throughput sequencing platform that enables the analysis of transcriptomes, genomes, and epigenomes. The platform is widely used in research and clinical applications.
• NanoString nCounter Analysis System: This system was launched in 2019 and enables the multiplexed analysis of gene expression in various sample types, including tissues, blood, and other bodily fluids. The platform is widely used in research, drug discovery, and clinical applications.
• Takara Bio SMARTer Stranded Total RNA-Seq Kit v3: This kit was launched in 2020 and enables the high-throughput analysis of stranded RNA-Seq libraries. The kit is widely used in research and drug discovery applications.
• Fluidigm C1 Single-Cell Auto Prep System: This system was launched in 2018 and enables the isolation and analysis of individual cells for gene expression analysis. The platform is widely used in research and drug discovery applications.

Download Free Sample Report

Market Segmentation

The global transcriptomics market can be segmented by component, by technology, by application, by end user and by region. Based on component, the market can be segmented into Instruments, Consumables, and Software & Services. Based on technology, the market can be differentiated into Next Generation Sequencing, Polymerase Chain Reaction, Microarray, In-Situ Hybridization, and Others. Based on application, the market can be segmented into Drug Discovery & Development, Cell Biology, Single Cell Analysis, Gene Expression, and Others. Based on end user, the market can be segmented into Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, United States dominated the global transcriptomics market on account of increasing demand for personalized medicine in the country.

Market Players

Agilent Technologies, Inc., ANGLE plc., Bio-Rad Laboratories, Inc., Becton, Dickinson, and Company, Fluidigm Corporation, BioSypder, Inc., Danaher Corporation (Cytiva), 10x Genomics, Inc., Pacific Biosciences of California, Inc., NanoString Technologies, Inc. are some of the leading players operating in the Global Transcriptomics Market.

Report Scope:

In this report, global transcriptomics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

         ·         Transcriptomics Market, By Component:

o    Instruments

o    Consumables

o    Software & Services

        ·         Transcriptomics Market, By Technology:

o   Next Generation Sequencing

o   Polymerase Chain Reaction

o   Microarray

o   In-Situ Hybridization

o   Others

        ·         Transcriptomics Market, By Application:

o   Drug Discovery & Development

o   Cell Biology

o   Single Cell Analysis

o   Gene Expression

o   Others

        ·         Transcriptomics Market, By End User:

o   Biotechnology & Pharmaceutical Companies

o   Academic & Research Institutions

o   Others

        ·         Transcriptomics Market, By Region:

o    North America

§  United States

§  Canada

§  Mexico

o    Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o    Asia Pacific

§  China

§  India

§  Japan

§  South Korea

§  Australia

o    South America

§  Brazil

§  Argentina

§  Colombia

o    Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Transcriptomics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Transcriptomics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]